Trials / Completed
CompletedNCT02843126
Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- Female
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is the safety and efficacy of Trastuzumab plus natural killer(NK) immunotherapy to recurrent breast cancer.
Detailed description
By enrolling patients who have breast cancer of Her-2 positive adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using Trastuzumab and NK cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab | Pre-dose (0 hours) on Day 1 of Cycles 1 to 8 (cycle length of 21 days) |
| BIOLOGICAL | NK immunotherapy | For each procedure, 10 billion cells will be infused for 4 times |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2017-07-01
- Completion
- 2019-07-01
- First posted
- 2016-07-25
- Last updated
- 2019-09-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02843126. Inclusion in this directory is not an endorsement.